estimates, price target were increased at Oppenheimer. Estimates were raised through 2014. Company can gain market share in Genotype 1 HCV, Oppenheimer said. Outperform rating and new $63 price target.
numbers raised at UBS. Earnings estimates were raised given better revenue outlook and buybacks, said UBS. Price target goes to $165.
Johnson & Johnson
(JNJ - Get Report)
numbers were boosted at Jefferies. Shares are now seen reaching $95. Estimates also upped, given better pharmaceuticals growth, Jefferies said. Hold rating.
price target was raised at Oppenheimer. Shares are now seen reaching $75. Company can continue to deliver strong sales and expand margins, Oppenheimer said. Outperform rating.
numbers were raised at UBS. Earnings estimates were raised given NIM upside, said UBS. Price target goes to $21.
>To submit a news tip, email:
and become a fan on